Skip to main content
SpringerLink
Log in

Gastric cancer – ASCO 2010

  • Short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Gastric cancer is still a devastating disease. Two thirds of the patients are diagnosed in a locally advanced or metastatic stage. Even if surgery is possible, long-term survival is low. Optimal therapy in a curative and a palliative setting is still not clear yet. ASCO 2010 could shed some light on optimal chemotherapy and the introduction of molecular targeted therapy. The aim of this article is to summarize the most important publications at this year's ASCO annual meeting and to put them into context of current therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Hohenberger P, Jensen K, Kieser M, Slanger TE. GE Adenocarcinoma Meta-analysis Group: Meta-analysis of preoperative chemotherapy (CTX) versus primary surgery for locoregionally advanced adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus (GE adenocarcinoma). J Clin Oncol, 28: 15s, 2010 (suppl; abstr 4022)

    Google Scholar 

  • Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355: 11–20, 2006

    Article  PubMed  CAS  Google Scholar 

  • Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol, 25: 18s 2007: abstract (4510)

    Google Scholar 

  • Wöll E, DeVries A, Eisterer W. et al. Chemotherapy in gastric cancer. Anticancer Res, 28: 1213–1220, 2008

    PubMed  Google Scholar 

  • Okines F, Langley R, Cafferty FH, Stenning SP, Falk S, seymour MT, Smith D, Middleton GW, Coxon FY, Cunningham D. Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma. J Clin Oncol, 28: 15s, 2010 (suppl; abstr 4019)

    Article  Google Scholar 

  • Lorenzen S, Panzram B, Rosenberg R, Becker K, Schenk U, Höfler H, Siewert JR, Ott K; Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric cancer undergoing a potentially curative resection. J Clin Oncol. 28: 15s, 2010 (suppl; abstr 4156)

    Google Scholar 

  • Shah MA, Shibata S, Stoller RG, Kemeny M, Ritch PS, Krishnamurthi SS, Su YB, Janjigian YY, Capanu M, Kelsen DP. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). J Clin Oncol 28: 15s, 2010 (suppl; abstr 4014)

    Article  Google Scholar 

  • Al-Batran S, Homann N, Hartmann JT, Moehler MH, Pauligk C, Probst S, Rethwisch V, Prasnikar N, Stoehlmacher J, Jaeger E. 5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol, 28: 15s, 2010 (suppl; abstr 4013)

    Google Scholar 

  • Thuss-Patience PC, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) J Clin Oncol, 27: 15s, 2009 (suppl; abstr 4540)

    Article  Google Scholar 

  • Takashima A, Boku N, Kato K, Mizusawa J, Nakamura K, Fukuda H, Shirao K, Shimada Y, Ohtsu A. Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): results from combined analysis of JCOG9205 and JCOG9912. J Clin Oncol, 28: 15s, 2010 (suppl; abstr 4061)

    Google Scholar 

  • Van Cutsem E, et al: Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer. J Clin Oncol, 27: 15s, 2009 (suppl; abstr LBA4511)

    Article  Google Scholar 

  • Chung HC, Bang Y, Van Cutsem E, Kang Y, Hamamoto Y, Moiseyenko V, Gotovkin E, Urspruch A, Ducournau P. (Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer. J Clin Oncol, 28: 15s, 2010 (suppl; abstr 4048)

    Google Scholar 

  • Kang Y, Ohtsu A, Van Cutsem E, Rha SY, Sawaki A, Park S, Lim H, Wu J, Langer B, Shah MA. AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol, 28: 18s, 2010 (suppl; abstr LBA4007)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Vinzenz Hospital Zams, Zams, Austria

    E. Wöll

Authors
  1. E. Wöll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Wöll.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wöll, E. Gastric cancer – ASCO 2010. memo 3, 168–170 (2010). https://doi.org/10.1007/s12254-010-0230-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-010-0230-7

Keywords

Search

Navigation